Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/19/2025

Diagnostic Approach to Trichomoniasis, Chlamydia, and Gonococcal Infections

Key Diagnostic Principles

  • The Centers for Disease Control and Prevention recommends that all three infections require laboratory confirmation because clinical diagnosis is unreliable 1, 2, 3
  • The American College of Obstetricians and Gynecologists suggests that nucleic acid amplification tests (NAATs) are the preferred diagnostic method with sensitivity >95% and specificity >99% for gonorrhea and chlamydia, and sensitivity 86-100% for trichomoniasis 3, 4

Diagnostic Algorithm

  • The Centers for Disease Control and Prevention recommends obtaining NAATs for all three pathogens simultaneously, with specimens collected from all sites of penetration: cervical/vaginal swabs in women, urethral swabs or urine in men, plus pharyngeal and rectal swabs if indicated by sexual history 1, 4
  • The American College of Obstetricians and Gynecologists suggests that self-collected vaginal swabs are FDA-cleared and acceptable for NAAT testing 3
  • The Centers for Disease Control and Prevention recommends testing all patients for all three pathogens plus HIV and syphilis due to high coinfection rates 3, 5

Diagnostic Testing

  • The Centers for Disease Control and Prevention suggests that wet mount microscopy can provide immediate results but has poor sensitivity, detecting motile trichomonads in only 50% of infected women 2, 6, 7
  • The American College of Obstetricians and Gynecologists recommends that Gram stain (men with urethral discharge only) has >99% specificity and >95% sensitivity for gonorrhea, but should not be used for women, asymptomatic men, or extragenital sites 4, 8, 6

Treatment and Follow-Up

  • The Centers for Disease Control and Prevention recommends treating empirically for gonorrhea and chlamydia in high-risk patients, with a recommended presumptive regimen of ceftriaxone 500 mg IM for gonorrhea PLUS azithromycin 1 g PO or doxycycline 100 mg PO twice daily for 7 days for chlamydia 1, 6
  • The American College of Obstetricians and Gynecologists suggests retesting all patients at 3 months after treatment for gonorrhea or chlamydia due to high reinfection rates 5
  • The Centers for Disease Control and Prevention recommends that test-of-cure is NOT routinely recommended unless symptoms persist, pregnancy is involved, or pharyngeal gonorrhea was treated 1

Partner Management

  • The Centers for Disease Control and Prevention recommends that all sex partners from the past 60 days must be notified, examined, and treated if any infection is diagnosed, with both patients and partners abstaining from intercourse for 7 days after single-dose therapy or until completion of 7-day regimens 3, 5, 6

REFERENCES

3

Testing for Chlamydia and Gonorrhea in Bacterial Vaginosis [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

4

Diagnostic Confirmation for Gonorrhea [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

5

STD Testing and Management Following Condom Failure [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025